Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Phase III NExUS trial of sorafenib in NSCLC does not meet primary endpoint

June 15, 2010

Telormedix begins phase I/II TMX-101 trial in non-muscle-invasive bladder cancer

June 15, 2010

R-7160 evaluated in phase I/II trial in solid tumors

June 15, 2010

UCB presents novel PI3K inhibitors

June 15, 2010

MGMTP140K-modified CD34+ stem cells efficiently engrafted into patients with glioblastoma

June 15, 2010

Nerviano Medical Sciences discloses new HSP 90 inhibitors

June 15, 2010

Cediranib to enter phase II trial in advanced biliary tract cancers

June 14, 2010

Trials suggest dasatinib or nilotinib could replace imatinib as first-line CML therapy

June 14, 2010

S*BIO completes enrollment in phase II SB-1518 trials in myelofibrosis

June 11, 2010

HGS reports phase II data on mapatumumab in advanced multiple myeloma

June 11, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...